What is Veru?
Veru Inc. operates as a sophisticated late clinical-stage biopharmaceutical entity, strategically headquartered in Miami, Florida. The company maintains a dual-focus business structure, encompassing both a dedicated Research and Development division and a Commercial segment. Its primary scientific objective centers on the development of novel therapeutics for cardiometabolic, inflammatory, and metabolic diseases, alongside a strong presence in oncology. Key assets in its pipeline include enobosarm, an oral selective androgen receptor modulator designed to mitigate muscle loss during weight loss therapy, and sabizabulin, a broad anti-inflammatory agent targeting atherosclerotic coronary artery disease and viral-induced respiratory distress. Beyond its clinical pipeline, Veru maintains a commercial footprint through its Urev division, which provides specialized sexual health products and urology pharmaceuticals, supported by a direct-to-patient telemedicine infrastructure.
How much funding has Veru raised?
Veru has raised a total of $350K across 1 funding round:
Debt
$350K
Debt (2020): $350K with participation from PPP
Key Investors in Veru
PPP
Public-Private Partnership
What's next for Veru?
With the recent capital injection, Veru is poised to prioritize the clinical progression of its lead candidates, specifically focusing on the regulatory pathways for enobosarm and sabizabulin. The strategic allocation of these funds will likely target the expansion of clinical trial sites and the enhancement of manufacturing capabilities to support potential commercialization. Furthermore, the company is expected to leverage its telemedicine platform to increase market penetration for its existing urology and sexual health portfolio. As Veru navigates the complexities of late-stage clinical development, the focus remains on achieving key data readouts that will validate its therapeutic platforms and drive long-term shareholder value in the competitive biopharmaceutical landscape.
See full Veru company page
